Novel approaches for long-term lung transplant survival.

Front Immunol · 2022 · PMC9363671 · PMID 35967365

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The inhaled pan-JAK inhibitor nezulcitinib (TD-0903, Theravance Biopharma) was used for treatment of COVID-19 associated lung injury in a Phase II clinical trial ( NCT04402866 ) but failed to meet its primary endpoint; however, the drug was well-tolerated and showed a trend towards decreased mortality and duration of hospitalization ( 192 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.